Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$418.3 million.

  • Tarsus Pharmaceuticals' Retained Earnings fell 2407.56% to -$418.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$418.3 million, marking a year-over-year decrease of 2407.56%. This contributed to the annual value of -$360.2 million for FY2024, which is 4723.12% down from last year.
  • Tarsus Pharmaceuticals' Retained Earnings amounted to -$418.3 million in Q3 2025, which was down 2407.56% from -$405.7 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Retained Earnings registered a high of -$16.1 million during Q2 2021, and its lowest value of -$418.3 million during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$163.6 million (2023), whereas its average is -$195.0 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Retained Earnings plummeted by 35088.07% in 2022, and later plummeted by 2407.56% in 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Retained Earnings (Quarter) stood at -$46.7 million in 2021, then crashed by 133.04% to -$108.8 million in 2022, then plummeted by 124.94% to -$244.7 million in 2023, then crashed by 47.23% to -$360.2 million in 2024, then dropped by 16.11% to -$418.3 million in 2025.
  • Its last three reported values are -$418.3 million in Q3 2025, -$405.7 million for Q2 2025, and -$385.3 million during Q1 2025.